Citing data from the All India Institute of Medical Sciences (AIIMS) Delhi, said the company, 2.5 AML cases occurred in approximately 1,00,000 people in India.
The American pharmaceutical company Abbvie has marked its entry into the segment of Indian cancer medications with venetoclax used to treat acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL).
AML is a strange and aggressive form of blood cancer with limited treatment options, said a company’s note. Venetoclax sacrifices a novel approach by selectively attacking cancer cells in the blood and bone marrow, providing an option for patients, particularly those who cannot undergo conventional intensive chemotherapy due to the age or other medication healing. The company’s medication. The company’s medication.
Citing data from the All India Institute of Medical Sciences (AIIMS) Delhi, said the company, 2.5 AML cases occurred in approximately 1,00,000 people in India. Venetoclax sacrifices an “oral dosing regime of the convent,” said the company, which supports a more personalized approach to care, “allowing doctors to adapt the treatment to the state of health and the tolerance of a patient a patient a significant consideration in the management of this aggressive
Suresh Patthil, general managing director and manager, ABBVIE India, said: “Our entrance to oncology in India means more than the launch of a single medication; it reflects our general commitment to advance cancer care.” Rahul Rathod, medical director, Abbvie, described the “different challenges” that India faced AML, including “late diagnosis, limited access to advanced therapies and a growing load of the disease among the aging population.”
Posted on April 21, 2025